Identifying Pediatric and Developmental Screening Targets With Biologically Informed Molecular Representations

More than 75% of Food and Drug Administration approved drugs lack pediatric dosing, efficacy, or safety data, and roughly 40% of medications prescribed to children are used off-label. For most therapies children receive, dose, formulation, or indication has never been formally evaluated in anyone under 18. In this work, we build on our previous model, BioMADE, to identify toxicity screening targets whose relevance is specific to defined developmental stages. We analyzed 3.8 million drug-condition records from KidSIDES across 7 developmental stages and 6 system organ classes. Univariate analysis identified biologically coherent genes associated with pediatric conditions, including known genes like GABRB1 (pathogenic variants cause developmental and epileptic encephalopathy), SLC6A1 (associated with developmental encephalopathies), and GRIN2A (defining gene of epilepsy-aphasia spectrum). Signals were the strongest in early life, spanning multiple organ systems. The highest univariate model was gene CTSS, area under the receiver operating characteristic curve of 0.776; 95% confidence interval 0.62-0.90. Multivariate models surpassed 0.8 area under receiving operator curve in 13 datasets (0.81-0.91), indicating that multi-gene drug interaction profiles carry predictive signal beyond single-target associations. We further identify secondary targets that may influence pediatric development and contribute to pediatric-specific adverse drug events, many of which are not included in current safety screening panels. Our findings support the development of novel pediatric-specific safety screening panels, with a particular emphasis on respiratory and congenital disorders in early life. Prioritizing relevant drug targets for pediatric screening can potentially reduce the challenges of pediatric clinical trials and advance safer, more precise pediatric drug therapies.

Authors

Institutions

Publication Details

Journal
Clinical Pharmacology & Therapeutics
Published
2026-11-13
DOI
https://doi.org/10.1002/cpt.70555
Primary Topic
Pharmaceutical studies and practices
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Identifying Pediatric and Developmental Screening Targets With Biologically Informed Molecular Representations

Martijn C. Schut, Nicholas P. Tatonetti, Jose Miguel Acitores Cortina
2 links
Clinical Pharmacology & Therapeutics
Pharmaceutical studies and practices
article

Identifying Pediatric and Developmental Screening Targets With Biologically Informed Molecular Representations

Martijn C. Schut, Nicholas P. Tatonetti, Jose Miguel Acitores Cortina
article en

Abstract

More than 75% of Food and Drug Administration approved drugs lack pediatric dosing, efficacy, or safety data, and roughly 40% of medications prescribed to children are used off-label. For most therapies children receive, dose, formulation, or indication has never been formally evaluated in anyone under 18. In this work, we build on our previous model, BioMADE, to identify toxicity screening targets whose relevance is specific to defined developmental stages. We analyzed 3.8 million drug-condition records from KidSIDES across 7 developmental stages and 6 system organ classes. Univariate analysis identified biologically coherent genes associated with pediatric conditions, including known genes like GABRB1 (pathogenic variants cause developmental and epileptic encephalopathy), SLC6A1 (associated with developmental encephalopathies), and GRIN2A (defining gene of epilepsy-aphasia spectrum). Signals were the strongest in early life, spanning multiple organ systems. The highest univariate model was gene CTSS, area under the receiver operating characteristic curve of 0.776; 95% confidence interval 0.62-0.90. Multivariate models surpassed 0.8 area under receiving operator curve in 13 datasets (0.81-0.91), indicating that multi-gene drug interaction profiles carry predictive signal beyond single-target associations. We further identify secondary targets that may influence pediatric development and contribute to pediatric-specific adverse drug events, many of which are not included in current safety screening panels. Our findings support the development of novel pediatric-specific safety screening panels, with a particular emphasis on respiratory and congenital disorders in early life. Prioritizing relevant drug targets for pediatric screening can potentially reduce the challenges of pediatric clinical trials and advance safer, more precise pediatric drug therapies.

Clinical Pharmacology & Therapeutics
Cedars-Sinai Medical Center (US), Amsterdam University Medical Centers (NL), Vrije Universiteit Amsterdam (NL), Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
National Institutes of Health, National Institute of General Medical Sciences
Good health and well-being
Pharmaceutical studies and practices
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon